Quantcast

Latest Tyrosine kinase inhibitors Stories

2010-08-23 16:01:00

NEW YORK, Aug. 23 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE :PFE) announced today that the SUN 1087 trial of sunitinib in combination with erlotinib versus erlotinib demonstrated a statistically significant improvement in Progression-Free but not in Overall Survival in patients with previously treated advanced non-small cell lung cancer (NSCLC). Overall survival was the primary endpoint of the study and Progression-Free Survival was a secondary endpoint of the study. No new or...

2010-08-18 03:10:10

CSHL-led team demonstrates that increased IL-6 secretion can lead to decreased sensitivity to Tarceva One of the most tantalizing developments in anti-cancer therapy over recent years has been the advent of targeted treatments, which have proven highly effective in holding aggressive cancers at bay in certain patients, although typically only for a limited period of time. A team led by Raffaella Sordella, Ph.D., an Assistant Professor at Cold Spring Harbor Laboratory (CSHL), today published...

2010-07-29 13:48:48

Scientists in Japan may have developed a way to accurately predict those patients who will resist treatment with imatinib, which is the standard of care for chronic myeloid leukemia (CML). Results are published in Clinical Cancer Research, a journal of the American Association for Cancer Research. Imatinib, currently sold as Gleevec by Novartis, revolutionized the treatment of leukemia when it was approved in 2001. Yet imatinib comes with its own set of problems, chiefly resistance. Although...

2010-06-29 08:00:00

WALTHAM, Mass., June 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2019, robust 4.1 percent annual growth in the renal cell carcinoma drug market will be driven primarily by the uptake of GlaxoSmithKline's Votrient/Patorma, the launches of premium-priced emerging therapies and an increase in diagnosed incidence and treatment rates. The Pharmacor 2010 findings from the topic...

2010-06-17 21:04:00

EAST HANOVER, N.J., June 17 /PRNewswire/ -- Following a priority review, the US Food and Drug Administration (FDA) has approved Tasigna® (nilotinib) 150 mg capsules for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The effectiveness of Tasigna is based on major molecular response and cytogenetic response rates. The study is ongoing and further data will be required to determine...

2010-06-17 16:34:00

Approval expands use in treatment of rare type of leukemia SILVER SPRING, Md., June 17 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a new indication for Tasigna (nilotinib) for the treatment of a rare blood cancer when it is first diagnosed. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a slowly progressing blood and bone marrow disease linked to a genetic abnormality. (Logo:...

2010-06-09 06:00:00

SINGAPORE, June 9 /PRNewswire/ -- S*BIO Pte Ltd today announced that it has completed enrollment of patients in two separate Phase 2 clinical trials for its potent and orally-active JAK2 inhibitor SB1518 at multiple clinical sites in the U.S. and Australia for the treatment of myelofibrosis (MF). These two multi-center, single-arm, open-label studies are designed to evaluate the efficacy and safety of SB1518 in patients with MF. Based on the clinical data derived from the Phase 1 trial,...

2010-06-07 08:14:00

LONDON, June 7, 2010 /PRNewswire-FirstCall/ -- Results from ZETA, a phase III study in patients with advanced medullary thyroid cancer (MTC), showed that treatment with the investigational drug vandetanib significantly extended Progression Free Survival (PFS), the primary endpoint of the study, by demonstrating a 54% reduction in the rate of progression compared to placebo (HR=0.46, p=0.0001). The results of the ZETA study were presented today at the American Society of Clinical Oncology...

2010-06-06 07:50:04

MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy Dasatanib, a medication currently approved as treatment for drug-resistant chronic myeloid leukemia (CML), provided patients with quicker, better responses as a first therapy than the existing front-line drug, according to researchers at The University of Texas MD Anderson Cancer Center. The findings were presented at the 46th Annual Meeting of the American Society of Clinical Oncology June...

2010-06-06 07:45:27

Phase III clinical trials show improved responses over standard of care Two drugs approved for treatment of drug-resistant chronic myeloid leukemia provide patients with quicker, better responses as a first therapy than the existing front-line medication, according to two studies published online by the New England Journal of Medicine. Separate international phase III clinical trials compared high-quality remissions after one year of treatment between the standard-of-care drug imatinib, also...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'